A Retrospective Claims Analysis of Dual Bronchodilator Fixed-Dose Combination Versus Bronchodilator Monotherapy in Patients with Chronic Obstructive Pulmonary Disease

• Published in: Chronic obstructive pulmonary diseases Vol. 6; no. 3; pp. 221 - 232
• Main Authors: Strange, Charlie, Walker, Valery, Tong, Junliang, Kurlander, Jonathan, Carlyle, Maureen, Millette, Lauren A, Wittbrodt, Eric
• Format: Journal Article
• Language: English
• Published: United States COPD Foundation Inc 24.07.2019
• Subjects: Original Research; retrospective analysis; long-acting beta2-agonist; LABA; LAMA/LABA; administrative claims; LAMA; fixed-dose combination; long-acting muscarinic antagonist; copd; chronic obstructive pulmonary disease
• ISSN: 2372-952X; 2372-952X
• DOI: 10.15326/jcopdf.6.3.2018.0160

Patients with chronic obstructive pulmonary disease (COPD) increasingly receive combination bronchodilator therapies. Real world evidence for the benefits of combination therapy compared to monotherapy is lacking. COPD patients aged ≥ 40 years initiating monotherapy (MT) with either a long-acting muscarinic antagonist (LAMA) or long-acting beta2-agonist (LABA) or dual therapy (DT) with a LAMA/LABA fixed dose combination (FDC) between January 1, 2016 and December 31, 2016 were identified from a large U.S. administrative claims database. Patients diagnosed with cystic fibrosis, idiopathic pulmonary fibrosis, or asthma were excluded. Cohorts were propensity score matched 1:1 using baseline measures (e.g., exacerbations, hospitalizations) as proxies for COPD severity to create balanced cohorts. Following propensity score matching (PSM), 1286 patients remained in each cohort for analysis. Patients were followed for approximately 1 year. Patients in the DT versus MT cohort had lower rates of exacerbations leading to hospitalization (incidence rate ratio 0.7886; =0.019), lower mean COPD-related pharmacy costs per patient per month (PPPM) ($300 versus $379, respectively; <0.001) and total costs PPPM ($990 versus $1203, respectively; =0.003). This occurred despite lower mean COPD-related pharmacy fills PPPM in the DT versus MT cohorts (1.41 versus 1.51, respectively; =0.038). Patients in the DT cohort had lower rates of switching ( <0.001) and augmentation ( <0.001), and higher rates of non-persistence ( <0.001) versus the MT cohort. Rates of discontinuation were similar. Patients in the DT cohort had lower rates of exacerbations leading to hospitalization, lower COPD-related pharmacy and total costs PPPM, and lower rates of switching and augmentation compared to patients in the MT cohort.